Bofanglutide
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Gan & Lee Pharmaceuticals · Phase 2 · Completed · Enrollment 326
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| 24 mg GZR18 group | Obesity or overweight | 24 mg | n/r | n/r | n/r |
| 36 mg GZR18 group | Obesity or overweight | 36 mg | n/r | n/r | n/r |
| 48 mg GZR18 group | Obesity or overweight | 48 mg | n/r | n/r | n/r |
| Tirzepatide group | Obesity or overweight | n/r | n/r | n/r | n/r |